Patent · US Active

TEC family kinase inhibitor adjuvant therapy

US9717731B2 · kind B2 · utility

9Cited by
4References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 1, 2013
Grant dateAug 1, 2017
Priority date—
Expiry dateNov 1, 2033

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.